1. Home
  2. NWL vs GENB Comparison

NWL vs GENB Comparison

Compare NWL & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Newell Brands Inc.

NWL

Newell Brands Inc.

HOLD

Current Price

$5.79

Market Cap

2.1B

Sector

Industrials

ML Signal

HOLD

GENB

Generate Biomedicines Inc. Common Stock

N/A

Current Price

$17.35

Market Cap

1.9B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
NWL
GENB
Founded
1903
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Plastic Products
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.9B
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
NWL
GENB
Price
$5.79
$17.35
Analyst Decision
Buy
Strong Buy
Analyst Count
9
6
Target Price
$4.97
$23.20
AVG Volume (30 Days)
15.3M
1.1M
Earning Date
05-01-2026
05-11-2026
Dividend Yield
7.11%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$14,742,200,000.00
N/A
Revenue This Year
$1.19
N/A
Revenue Next Year
$1.58
$16.58
P/E Ratio
N/A
N/A
Revenue Growth
11.14
N/A
52 Week Low
$3.07
$11.00
52 Week High
$6.64
$18.18

Technical Indicators

Market Signals
Indicator
NWL
GENB
Relative Strength Index (RSI) 70.20 66.93
Support Level $3.32 $11.73
Resistance Level N/A N/A
Average True Range (ATR) 0.35 1.22
MACD 0.09 0.29
Stochastic Oscillator 77.12 87.19

Price Performance

Historical Comparison
NWL
GENB

About NWL Newell Brands Inc.

Newell Brands Inc is an American consumer goods company with a portfolio of brands, including Rubbermaid, Sharpie, Graco, Coleman, Rubbermaid Commercial Products, Yankee Candle, Paper Mate, FoodSaver, Dymo, EXPO, Elmer's, Oster, NUK, Spontex and Campingaz. The group is focused on delighting consumers by lighting up everyday moments. Its segments are Home and Commercial Solutions, Learning and Development, and Outdoor and Recreation. The group geographic areas are the United States, Canada, Europe, the Middle East and Africa, Asia Pacific, and Latin America.

About GENB Generate Biomedicines Inc. Common Stock

Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.

Share on Social Networks: